Skip to content

Characterization and Epigenetics of Post-Partum Preeclampsia

Characterization and Epigenetics of Post-Partum Preeclampsia

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02935556
Enrollment
12
Registered
2016-10-17
Start date
2017-02-01
Completion date
2022-03-09
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Partum Pre-eclampsia

Keywords

Post Partum Pre-eclampsia

Brief summary

This study will recruit women with post partum pre-eclampsia and match them to controls without postpartum pre-eclampsia to identify an epigenetic signature that is specific to women with post partum pre-eclampsia to help characterize the underlying pathophysiology of post partum pre-eclampsia.

Detailed description

Preeclampsia (PEC) is a heterogeneous disease that complicates 5-8% of pregnancies. Approximately 10% of PEC patients will present with post-partum PEC without having developed the syndrome during the pregnancy (PP-PEC). Management of post-partum preeclampsia (PP-PEC) is challenging because many women do not seek care until neurologic symptoms result from severe-range elevated blood pressure. The pathogenesis and clinical characteristics of PP-PEC are understudied and poorly understood. Identifying clinical risk factors and biomarkers of PP-PEC would help to identify women at risk.

Interventions

OTHERno intervention

database and epigenetic study

Sponsors

New York University
CollaboratorOTHER
Society for Obstetric Anesthesia and Perinatology
CollaboratorOTHER
Duke University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Post partum pre-eclampsia Matching based on: * maternal age (years +/-3) * BMI (+/-5 points) * Ethnicity * Mode of delivery * Gestational age at delivery (+/7 days) * Smoking status

Exclusion criteria

* Intrapartum pre-eclampsia

Design outcomes

Primary

MeasureTime frame
methylation signature on circulating monocytes1 week post delivery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026